

Onglyza® (saxagliptin) - First-time generic

- On August 1, 2023, Viatris launched an <u>AB-rated</u> generic version of AstraZeneca's <u>Onglyza</u> (saxagliptin) tablets.
 - Aurobindo, Glenmark and Sun received FDA approval of AB-rated generic versions of Onglyza on July 31, 2023; Aurobindo and Glenmark are expected to launch their generics in the next week. Sun's launch plans for generic Onglyza are pending.
- Onglyza is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.